When comparing vellux botulinum toxin to established brands like Botox, Dysport, Xeomin, and Jeuveau, the key differences lie in its molecular formulation, unit potency, diffusion characteristics, speed of onset, duration of effect, and price point. These factors are critical for practitioners when selecting the most appropriate product for a specific treatment area and desired outcome.
Molecular Composition and Manufacturing
At the core of each brand's identity is its molecular structure. All botulinum toxin type A products consist of the core 150kDa neurotoxin, but they differ in the presence of complexing proteins.
Vellux, similar to Botox and Jeuveau, is presented as a 900kDa complex. This means the active neurotoxin is surrounded by accessory proteins (hemagglutinin and non-toxin non-hemagglutinin proteins). The theory is that these proteins act as stabilizers, protecting the neurotoxin during the lyophilization (freeze-drying) process and reconstitution. In contrast, Xeomin is often referred to as "naked" toxin because it is a 150kDa pure neurotoxin, purified to remove the complexing proteins. The manufacturer of Xeomin, Merz, claims this reduces the potential for antibody development, though the rate of neutralizing antibody formation for all modern formulations is exceptionally low (estimated at less than 1-1.5%). Dysport, like Vellux and Botox, is a complexed formulation.
The manufacturing process itself, including the specific bacterial strain used and the purification techniques, is proprietary to each company. Vellux is produced by the South Korean biopharmaceutical company Huons, a company with a strong reputation in the field of toxins and fillers. This pedigree is a significant factor in its growing acceptance.
Unit Potency and Conversion Ratios
This is one of the most critical and potentially confusing aspects for practitioners. The units of measurement for botulinum toxin (U) are specific to each product and are not interchangeable. A unit of Vellux is not the same as a unit of Botox or Dysport.
Vellux's unit potency is calibrated to be highly similar to that of Botox (onabotulinumtoxinA). Most clinical studies and user reports suggest a 1:1 conversion ratio between Vellux and Botox. This means if a treatment plan calls for 20 units of Botox, a practitioner would typically administer 20 units of Vellux to achieve a comparable effect.
The contrast is stark when compared to Dysport (abobotulinumtoxinA), which has a much lower unit potency but a higher diffusivity. The generally accepted conversion ratio from Botox to Dysport is 1:2.5 or even 1:3. So, that same 20-unit Botox dose might equate to 50-60 units of Dysport.
The following table illustrates these key conversion differences:
| Brand | Molecular Form | Typical Conversion Ratio (vs. Botox) | Notable Characteristic |
|---|---|---|---|
| Botox (OnabotulinumtoxinA) | 900kDa Complex | 1:1 (Baseline) | Gold standard, predictable diffusion |
| Vellux (PrabotulinumtoxinA) | 900kDa Complex | 1:1 | Similar potency and profile to Botox |
| Dysport (AbobotulinumtoxinA) | 500-900kDa Complex | 1:2.5 | Higher diffusion, faster onset |
| Xeomin (IncobotulinumtoxinA) | 150kDa "Naked" | 1:1 | No complexing proteins |
| Jeuveau (PrabotulinumtoxinA) | 900kDa Complex | 1:1 | Bio-identical to Vellux, marketed for aesthetics |
It is crucial to note that Jeuveau (also known as Nabota) is the same molecule as Vellux, both being prabotulinumtoxinA developed by Huons. Jeuveau is the trade name for the product licensed and marketed in the United States and certain other territories by Evolus, while Vellux is the trade name used elsewhere.
Diffusion Profile and Clinical Implications
Diffusion refers to how far the toxin spreads from the injection site. This characteristic directly influences which areas the toxin is best suited for.
Vellux exhibits a moderate, controlled diffusion profile that is very comparable to Botox. This makes it an excellent choice for precision work where you want to limit the effect to a specific muscle. Ideal applications for this profile include:
- Glabellar lines (frown lines): Precise targeting of the corrugator and procerus muscles without affecting the levator palpebrae superioris (which can cause ptosis or drooping eyelid).
- Horizontal forehead lines: Targeted injection into the frontalis muscle with minimal risk of migration.
- Crow's feet (lateral canthal lines): Careful placement around the orbital rim to avoid affecting muscles responsible for smile and cheek elevation.
In contrast, Dysport is known for its wider diffusion radius. This can be advantageous when treating larger muscle areas, such as the platysmal bands in the neck or the frontalis muscle (where a broader, more even softening is desired). However, its higher diffusion also requires greater caution in areas like the glabella to prevent unwanted spread.
Xeomin's diffusion is considered similar to Botox, while Jeuveau's, being identical to Vellux, is also comparable.
Onset of Action and Duration of Effect
Patients are always interested in how quickly they will see results and how long those results will last.
The onset of action for Vellux is typically 2-4 days, with maximal effect visible at around 7-14 days. This is on par with Botox and Xeomin. Dysport often has a slightly faster onset, with some patients noticing effects within 24-48 hours.
Regarding duration, most patients experience a return of muscle activity between 3 to 4 months after treatment with Vellux. This is consistent with the duration observed with Botox, Xeomin, and Jeuveau in the majority of patients. Dysport's duration is sometimes reported to be slightly shorter, averaging 3-3.5 months for some individuals, though this can vary significantly based on the patient's metabolism, dose, and treatment area. It's important to manage patient expectations that duration can be influenced by individual factors, and the first treatment may not last as long as subsequent ones.
Reconstitution, Storage, and Cost Considerations
From a practical clinic standpoint, handling and cost are significant factors.
Vellux, like other toxins, requires reconstitution with sterile saline. The concentration used (e.g., 100U/2.5mL vs. 100U/1mL) can influence its diffusion—higher volumes (more dilute) can lead to slightly greater diffusion. It is stored in a refrigerator at 2-8°C.
The most prominent differentiator for Vellux is often its cost-effectiveness. As a newer entrant aiming to compete with the market leader (Botox), Vellux is typically priced lower per unit. This allows practitioners to either reduce the cost to the patient or maintain their pricing while achieving a better margin. This economic advantage has made it a popular choice for both clinics and patients seeking a high-quality, proven neurotoxin at a more accessible price point. It offers a compelling value proposition without compromising on the clinical efficacy and safety profile that practitioners expect.
Safety and Side Effect Profile
All approved botulinum toxin type A products have an excellent safety profile when administered by a trained medical professional. The side effects are generally local and temporary. Common side effects across all brands, including Vellux, can include injection site pain, redness, swelling, bruising, and headache. Asymmetry can occur but is usually technique-related rather than product-specific. The risk of more serious adverse events, such as ptosis (eyelid droop) or diffusion affecting nearby muscles, is minimized by proper anatomical knowledge, injection technique, and dose selection. The safety data for Vellux, underpinned by the clinical studies required for its approval, supports its position as a safe and effective alternative.